# Nimotuzumab Combined With Paclitaxel for Recurrent Metastatic Gastric or Esophagogastric Junction Adenocarcinoma

> **NCT05978050** · PHASE3 · RECRUITING · sponsor: **Biotech Pharmaceutical Co., Ltd.** · enrollment: 354 (estimated)

## Conditions studied

- Gastric or Esophagogastric Junction Adenocarcinoma

## Interventions

- **DRUG:** nimotuzumab plus paclitaxel
- **DRUG:** placebo plus paclitaxel

## Key facts

- **NCT ID:** NCT05978050
- **Lead sponsor:** Biotech Pharmaceutical Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-01
- **Primary completion:** 2026-03-01
- **Final completion:** 2026-03-01
- **Target enrollment:** 354 (ESTIMATED)
- **Last updated:** 2024-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05978050

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05978050, "Nimotuzumab Combined With Paclitaxel for Recurrent Metastatic Gastric or Esophagogastric Junction Adenocarcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05978050. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*